RecruitingPhase 2NCT07522099

Chinese Adults With Kidney Disease

A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Sponsor

ADARx Pharmaceuticals, Inc.

Enrollment

30 participants

Start Date

May 21, 2026

Study Type

INTERVENTIONAL

Conditions

Immunoglobulin A Nephropathy (IgAN)IC-MPGN Complement 3 Glomerulopathy (C3G)

Summary

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ADX-038 and a drug called Telitacicept for people with complement 3 glomerulopathy (c3g), ic-mpgn, and other related conditions. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGADX-038

siRNA duplex oligonucleotide

DRUGTelitacicept

fusion protein

Locations(10)

ADARx Clinical Site

Shenzhen, Guangdong, China

ADARx Clinical Site

Guiyang, Guizhou, China

ADARx Clinical Site

Zhengzhou, Henan, China

ADARx Clinical Site

Baotou, Inner Mongolia, China

ADARx Clinical Site

Wuxi, Jiangsu, China

ADARx Clinical Site

Yantai, Shandong, China

ADARx Clinical Site

Beijing, China

ADARx Clinical Site

Shandong, China

ADARx Clinical Site

Shanghai, China

ADARx Clinical Site

Shangxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07522099

Related Trials

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT0698935929 locations

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357240 locations

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386130 locations

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT071469069 locations